Drug Approval | May 25, 2026
EU regulator backs Allergan Aesthetics’ Boey in key step toward approval
The decision marks a key step in the centralized EU review process
The decision marks a key step in the centralized EU review process
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
